June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
|Videos|December 12, 2020
Evaluating long-term safety of micro-bypass implant with phaco in PXG
Author(s)David Hutton, Alex Delaney-Gesing
Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.
Advertisement
Tanner Ferguson, MD, an ophthalmology resident at the Cleveland Clinic's Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.
Advertisement
Related to this article
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
NCX 470 glaucoma drop gains China regulatory encouragement, clearing path for near-term filings and expanding commercial upside beyond the US.
A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.
The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
One day, three approvals: FDA expands options for ocular redness, thyroid eye disease, and presbyopia
2
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
3
Diabetic macular edema: an inflammatory disease in focus
4
AAO 2026: GLP-1RA initiation not linked to anti-VEGF burden in DME
5